세계의 전자 약물 전달 장치 시장 : 규모, 점유율, 동향 분석(제품별, 용도별, 지역별), 부문별 예측(2025-2030년)

Electronic Drug Delivery Devices Market Growth & Trends:

The global electronic drug delivery devices market size is anticipated to reach USD 99.5 billion by 2030 and is anticipated to grow at a CAGR of 8.14% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth can be attributed to the increasing the growing geriatric population and prevalence of chronic diseases, increasing awareness for personalized medicine, rising preference for home healthcare, and the integration of digital technologies. For instance, in June 2024, AptarGroup, Inc. collaborated with SHL Medical to integrate Aptar Digital Health's SaMD platform with SHL Medical's advanced drug delivery systems, such as autoinjectors, pen injectors, and specialty delivery systems.

As patients are increasingly preferring to manage their health conditions at home, there is a growing demand for drug delivery devices that enable safe, effective, and easy at-home treatments. Devices such as insulin pumps, auto-injectors, wearable infusion pumps, and pre-filled syringes are becoming indispensable tools in home healthcare because they allow patients to self-administer medications with minimal assistance, offering both convenience and autonomy. For instance, in October 2023, Victrex plc, known for its innovative PEEK biomaterial solutions, introduced an advanced product, the VICTREX PC101 grade, specifically designed for drug delivery and pharmaceutical contact applications. This launch aligns with the growing trend of utilizing drug delivery devices in homecare environments, enhancing accessibility for patients seeking innovative solutions.

Moreover, technology trends in the electronic drug delivery devices market are rapidly advancing, driven by the need for greater precision, personalization, and patient convenience. Some of the new trends include the integration of digital health technologies, wearable drug delivery devices, and the use of microfluidics. The rise of precision medicine is also driving innovation. The devices are being tailored to the individual's genetic makeup, condition, or specific therapeutic needs, ensuring better outcomes and fewer side effects.

Electronic Drug Delivery Devices Market Report Highlights:

• Based on product, the implantable drug delivery devices segment dominated the market with the largest revenue share of 33.0% in 2024 owing to reduced side effects, controlled drug release, and their ability to provide localized treatment.
• Based on application, the diabetes segment accounted for the largest revenue share in 2024 due to its high prevalence and growing patient population, technological advancements in diabetes care, growing market demand, and reimbursement support.
• Based on region, North America held the largest revenue share of over 43.4% in 2024. This can be attributed to technological advancements, an increasing prevalence of chronic diseases, and rising demand for patient-centric drug delivery solutions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Electronic Drug Delivery Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases and growing geriatric population
    • 3.2.1.2. Rising preference for home healthcare
    • 3.2.1.3. Integration of digital technologies and growing awareness of personalized medications
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced drug delivery devices
    • 3.2.2.2. Limited patient awareness and device-related complications
• 3.3. Key Technology Trends
• 3.4. Key Brands
• 3.5. Pipeline Analysis
• 3.6. Electronic Drug Delivery Devices Market Analysis Tools
  • 3.6.1. Industry Analysis - Porter's
    • 3.6.1.1. Bargaining power of suppliers
    • 3.6.1.2. Bargaining power of buyers
    • 3.6.1.3. Threat of substitutes
    • 3.6.1.4. Threat of new entrants
    • 3.6.1.5. Competitive rivalry
  • 3.6.2. PESTEL Analysis
    • 3.6.2.1. Political landscape
    • 3.6.2.2. Economic landscape
    • 3.6.2.3. Social landscape
    • 3.6.2.4. Technological landscape
    • 3.6.2.5. Environmental landscape
    • 3.6.2.6. Legal landscape

Chapter 4. Electronic Drug Delivery Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Electronic Drug Delivery Devices Market: Product Movement Analysis
• 4.3. Electronic Drug Delivery Devices Market by Product Outlook (Revenue, USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Smart Infusion Pumps (Infusion Systems)
  • 4.5.1. Smart Infusion Pumps (Infusion Systems) Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.5.1.1. Non-biologic Smart Infusion Systems
      • 4.5.1.1.1. Non-biologic Smart Infusion Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.5.1.2. Biologic Smart Infusion Systems
      • 4.5.1.2.1. Biologic Smart Infusion Systems Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
        • 4.5.1.2.1.1. Smart Infusion Insulin Pumps
          • 4.5.1.2.1.1.1. Smart Infusion Insulin Pumps Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
        • 4.5.1.2.1.2. Others
          • 4.5.1.2.1.2.1. Others Market Revenue Estimated and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 4.6. Smart Metered Dose Inhalers (Inhalation Devices)
  • 4.6.1. Smart Metered Dose Inhalers (Inhalation Devices) Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 4.7. Implantable Drug Delivery Devices
  • 4.7.1. Implantable Drug Delivery Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.7.1.1. Biologic Implantable Drug Delivery Devices
      • 4.7.1.1.1. Biologic Implantable Drug Delivery Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
    • 4.7.1.2. Non-biologic Implantable Drug Delivery Devices
      • 4.7.1.2.1. Non-biologic Implantable Drug Delivery Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 5. Electronic Drug Delivery Devices Market: Application Estimated & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Electronic Drug Delivery Devices Market: Application Movement Analysis
• 5.3. Electronic Drug Delivery Devices Market by Application Outlook (Revenue, USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Diabetes
  • 5.5.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.6. Respiratory Diseases
  • 5.6.1. Respiratory Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.7. Oncology
  • 5.7.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.8. Cardiology
  • 5.8.1. Cardiology Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Electronic Drug Delivery Devices Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Regional Electronic Drug Delivery Devices Market Movement Analysis
• 6.3. Electronic Drug Delivery Devices Market: Regional Estimates & Trend Analysis by Product
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. North America
  • 6.5.1. North America Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. U.S.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. U.S. Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. Canada
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Canada Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. Mexico Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Europe
  • 6.6.1. Europe Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. UK
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. UK Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Germany
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. Germany Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.4. France
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement scenario
    • 6.6.4.5. France Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.5. Italy
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement scenario
    • 6.6.5.5. Italy Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.6. Spain
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement scenario
    • 6.6.6.5. Spain Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.7. Denmark
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement scenario
    • 6.6.7.5. Denmark Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.8. Sweden
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Competitive Scenario
    • 6.6.8.3. Regulatory Framework
    • 6.6.8.4. Reimbursement scenario
    • 6.6.8.5. Sweden Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.9. Norway
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Competitive Scenario
    • 6.6.9.3. Regulatory Framework
    • 6.6.9.4. Reimbursement scenario
    • 6.6.9.5. Norway Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Asia Pacific Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. Japan
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. Japan Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. China
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. China Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. India
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. India Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Reimbursement scenario
    • 6.7.5.5. South Korea Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.6. Australia
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Reimbursement scenario
    • 6.7.6.5. Australia Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.7. Thailand
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Reimbursement scenario
    • 6.7.7.5. Thailand Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.8. Latin America
  • 6.8.1. Latin America Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.8.2. Brazil
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement scenario
    • 6.8.2.5. Brazil Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.8.3. Argentina
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement scenario
    • 6.8.3.5. Argentina Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.9. Middle East & Africa
  • 6.9.1. Middle East & Africa Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.2. South Africa
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. Reimbursement scenario
    • 6.9.2.5. South Africa Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.3. Saudi Arabia
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Reimbursement scenario
    • 6.9.3.5. Saudi Arabia Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.4. UAE
    • 6.9.4.1. Key Country Dynamics
    • 6.9.4.2. Competitive Scenario
    • 6.9.4.3. Regulatory Framework
    • 6.9.4.4. Reimbursement scenario
    • 6.9.4.5. UAE Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.9.5. Kuwait
    • 6.9.5.1. Key Country Dynamics
    • 6.9.5.2. Competitive Scenario
    • 6.9.5.3. Regulatory Framework
    • 6.9.5.4. Reimbursement scenario
    • 6.9.5.5. Kuwait Electronic Drug Delivery Devices Market Estimates and Forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
• 7.2. Key Company Profiles
  • 7.2.1. Medtronic plc
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Insulet Corporation
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Becton, Dickinson and Company
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Tandem Diabetes Care, Inc.
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Ypsomed AG
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Novo Nordisk A/S
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Sanofi S.A.
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. Eli, Lilly and Company
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. AstraZeneca plc
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. GlaxoSmithKline plc
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Boehringer Ingelheim International GmbH
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Pfizer, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives
  • 7.2.13. Teva Pharmaceutical Industries
    • 7.2.13.1. Company overview
    • 7.2.13.2. Financial performance
    • 7.2.13.3. Product benchmarking
    • 7.2.13.4. Strategic initiatives
  • 7.2.14. Phillips-Medisize, LLC
    • 7.2.14.1. Company overview
    • 7.2.14.2. Financial performance
    • 7.2.14.3. Product benchmarking
    • 7.2.14.4. Strategic initiatives
  • 7.2.15. West Pharmaceutical Services, Inc.
    • 7.2.15.1. Company overview
    • 7.2.15.2. Financial performance
    • 7.2.15.3. Product benchmarking
    • 7.2.15.4. Strategic initiatives
  • 7.2.16. Gerresheimer AG
    • 7.2.16.1. Company Overview
    • 7.2.16.2. Financial performance
    • 7.2.16.3. Product benchmarking
    • 7.2.16.4. Strategic initiatives
  • 7.2.17. Nemera Group
    • 7.2.17.1. Company overview
    • 7.2.17.2. Financial performance
    • 7.2.17.3. Product benchmarking
    • 7.2.17.4. Strategic initiatives
  • 7.2.18. SHL Group
    • 7.2.18.1. Company overview
    • 7.2.18.2. Financial performance
    • 7.2.18.3. Product benchmarking
    • 7.2.18.4. Strategic initiatives
  • 7.2.19. Owen Mumford
    • 7.2.19.1. Company overview
    • 7.2.19.2. Financial performance
    • 7.2.19.3. Product benchmarking
    • 7.2.19.4. Strategic initiatives
  • 7.2.20. Haselmeier AG
    • 7.2.20.1. Company overview
    • 7.2.20.2. Financial performance
    • 7.2.20.3. Product benchmarking
    • 7.2.20.4. Strategic initiatives
  • 7.2.21. ICU Medical
    • 7.2.21.1. Company overview
    • 7.2.21.2. Financial performance
    • 7.2.21.3. Product benchmarking
    • 7.2.21.4. Strategic initiatives
  • 7.2.22. Hisamitsu Pharmaceutical Co., Inc.
    • 7.2.22.1. Company overview
    • 7.2.22.2. Financial performance
    • 7.2.22.3. Product benchmarking
    • 7.2.22.4. Strategic initiatives
  • 7.2.23. Sparsha Pharma International
    • 7.2.23.1. Company overview
    • 7.2.23.2. Financial performance
    • 7.2.23.3. Product benchmarking
    • 7.2.23.4. Strategic initiatives
  • 7.2.24. Baxter International, Inc.
    • 7.2.24.1. Company overview
    • 7.2.24.2. Financial performance
    • 7.2.24.3. Product benchmarking
    • 7.2.24.4. Strategic initiatives
  • 7.2.25. Fresenius Kabi AG
    • 7.2.25.1. Company overview
    • 7.2.25.2. Financial performance
    • 7.2.25.3. Product benchmarking
    • 7.2.25.4. Strategic initiatives
  • 7.2.26. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 7.2.26.1. Company overview
    • 7.2.26.2. Financial performance
    • 7.2.26.3. Product benchmarking
    • 7.2.26.4. Strategic initiatives
  • 7.2.27. Novartis AG
    • 7.2.27.1. Company overview
    • 7.2.27.2. Financial performance
    • 7.2.27.3. Product benchmarking
    • 7.2.27.4. Strategic initiatives
  • 7.2.28. AptarGroup, Inc.
    • 7.2.28.1. Company overview
    • 7.2.28.2. Financial performance
    • 7.2.28.3. Product benchmarking
    • 7.2.28.4. Strategic initiatives
  • 7.2.29. Teleflex Incorporates
    • 7.2.29.1. Company overview
    • 7.2.29.2. Financial performance
    • 7.2.29.3. Product benchmarking
    • 7.2.29.4. Strategic initiatives
  • 7.2.30. Abbott Laboratories
    • 7.2.30.1. Company overview
    • 7.2.30.2. Financial performance
    • 7.2.30.3. Product benchmarking
    • 7.2.30.4. Strategic initiatives